Neoadjuvant Pembrolizumab plus Chemotherapy Versus Placebo plus Chemotherapy, Followed by Adjuvant Pembrolizumab Versus Placebo for Early-Stage Tnbc: Event-Free Survival Sensitivity and Subgroup Analyses from Keynote-522

AuthID
P-00X-FG9
30
Author(s)
Cortes, J
·
Dent, R
·
Pusztai, L
·
McArthur, H
·
Kummel, S
·
Bergh, J
·
Denkert, C
·
Park, YH
·
Hui, RN
·
[+10]·
Im, SA
·
Ahn, JH
·
Gion, M
·
Baron-Hay, S
·
Boileau, JF
·
Zhu, YL
·
Pan, W
·
Tryfonidis, K
·
Karantza, V
·
O'Shaughnessy, J
Document Type
Abstract
Year published
2022
Published
in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, ISSN: 1743-7555
Volume: 18, Pages: 117-118 (2)
Indexing
Publication Identifiers
Wos: WOS:000871956500162
Source Identifiers
ISSN: 1743-7555
Export Publication Metadata
Marked List
Info
At this moment we don't have any links to full text documens.